The content on this site is intended for healthcare professionals only
Promising new data on drug combinations to treat metastatic melanoma are presented at a press conference from the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
“These studies exemplify an important landmark of some tumours, which has emerged from recent laboratory research: the presence of specific mutations, such as the BRAF mutation in metastatic melanoma which exposes an Achilles' heel--MEK in this case,” said Prof Yossef Yarden from the Weizmann Institute of Science, Israel.
ecancerNews Coverage from ESMO 2012
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Choosing the right patients for transplant
ESMO 2024: Latest in EGFR mutated NSCLC
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma
